Management of lung cancer is an area where SIFT-MS has real potential. In the UK, just under 40,000 people are diagnosed with lung cancer each year. More important, it is the UK’s most common cause of cancer death for both men (24% of all cancer deaths) and women (20% of all cancer deaths). As early stage diagnosis is associated with increased survival rates, it is hypothesised that the detection of VOCs released by lung cancer cells would improve early diagnosis and prognosis. At present, assessment of a tumour’s response to treatment still relies heavily on imaging techniques such as chest X-Rays and CT scans. There is, therefore, great potential for a cheaper, on-line, radiation-free and non-invasive system that is capable of detecting and managing diseases, such as lung cancer. This is something that breath analysis and SIFT-MS may be able to offer in the near future.
|Non invasive breath analysis—|
Dr JosepSulé-Suso (right) with PhD student Abigail Rutter (left).